Brands and Products
Chemours uses the power of chemistry to create better, reliable solutions.
The future of transport is here.
Discover how Chemours is driving innovation in the Electric Vehicle space with our latest line of advanced performance materials.
Sustainability
Creating a better world through responsible chemistry.
Our 2030 Goals
Our progress towards achieving Chemours’ Corporate Responsibility Commitment goals
Critical Chemistries
Chemours is working to create a better world through the power of our chemistry.
Showing 1-10 of 17 results for "R142b"
Vertrel™ specialty fluids act as fluorinated solvents, cleaners, and more.
First Quarter 2017 Highlights Net Sales of $1.4 billion , up 11%, including impacts from divestitures Net Income of $150 million , up $99 million with EPS of $0.79 , up $0.51 per diluted share Adjusted EBITDA of $285 million , up 123%, demonstrating margin improvement across all segments Adjusted Net Income of $142 million , up $131 million with Adjusted EPS of $0.75 , up $0.69 per diluted share A...
Full Year 2019 Results In-line with Updated Guidance Full Year 2019 Results Net Sales of $5.5 billion Net Income of $(52) million with EPS of $(0.32) Adjusted Net Income of $419 million with Adjusted EPS of $2.51 Adjusted EBITDA of $1.02 billion Free Cash Flow of $169 million Returned $486 million to shareholders through share repurchases and dividends Fourth Quarter 2019 Results Net Sales of $1.4...
Vertrel™ XSi is specially designed for use in the medical industry.
Documents have been submitted by The Chemours Company.
Second Quarter 2017 Highlights Net Sales of $1.6 billion , up 15% Net Income of $161 million , up $179 million with EPS of $0.84 , up $0.94 per diluted share Adjusted EBITDA of $361 million , up $174 million , driven by strong year-over-year volume and price improvement in Titanium Technologies and Fluoroproducts Adjusted Net Income of $166 million , up $117 million with Adjusted EPS of $0.87 , up...
The Board of Directors of The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) has appointed Denise Dignam as the Interim Chief Executive Officer and Matt Abbott as the Interim Chief Financial Officer (principal financial and accounting officer).
On March 18, 2024, The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) received notice from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023, with the Securities and Exchange Commission (the “SEC”).
Continued strength in APM and TSS despite uncertain macroeconomic conditions The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, today announced its financial results for the third quarter 2022.
Continuing to Aggressively Return Capital to Shareholders First Quarter 2019 Highlights Net Sales of $1.4 billion Net Income of $94 million, with EPS of $0.55 Adjusted Net Income of $109 million, with Adjusted EPS of $0.63 Adjusted EBITDA of $262 million Returned $261 million to shareholders through share repurchases The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leadi...
Use our database to access product SDS.
Chemours delivers valuable solutions to various industries around the globe.
The world depends on the power of chemistry.